Status:
UNKNOWN
Microarray CGH Analysis of Circulating Tumoral Plasma DNA in NF1 Patients With MPNSTs
Lead Sponsor:
KU Leuven
Conditions:
Neurofibromatosis Type 1
Eligibility:
All Genders
Brief Summary
Neurofibromatosis type 1 (NF1) is a frequent autosomal dominant disorder, caused by heterozygous mutations of the NF1 tumor suppressor gene (chr.17q11.2). One of the main clinical features is the deve...
Detailed Description
Introduction Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder occuring in 1 out of 3500 living newborns. The disease is caused by heterozygous mutations of the NF1 gene, located on chr...
Eligibility Criteria
Inclusion
- according to NF1 criteria
Exclusion
- NF1 patients where the tumor is already removed
Key Trial Info
Start Date :
October 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2011
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01218152
Start Date
October 1 2010
End Date
December 1 2011
Last Update
October 11 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
KULeuven/UZLeuven
Leuven, Vlaams-Brabant, Belgium, 3000